Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytori Therapeutics Inc    CYTX

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 9,71 M
EBIT 2017 -27,5 M
Net income 2017 -27,6 M
Debt 2017 -
Yield 2017 -
Sales 2018 19,7 M
EBIT 2018 -13,2 M
Net income 2018 -15,2 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 3,38x
Capi. / Sales2018 1,67x
Capitalization 32,8 M
More Financials
Company
Cytori Therapeutics, Inc. is a late stage cell therapy company. that engages in the developement of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions.Data from preclinical studies and clinical trials suggest that Cytori Cell... 
More about the company
Surperformance© ratings of Cytori Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on CYTORI THERAPEUTICS INC
06/16 CYTORI THERAPEUTICS : Submission of Matters to a Vote of Security Holders (form ..
06/14 Cytori® Partners with myTomorrows for Managed Access Program for Europe, Midd..
06/09 CYTORI THERAPEUTICS : Long Term Safety Data Published on Cytori Technology for B..
06/08 Long Term Safety Data Published on Cytori Technology for Breast Reconstructio..
06/01 Cytori to Introduce Next-Generation Celution® Technology
05/31 CYTORI THERAPEUTICS, INC. (NASDAQ : CYTX) Files An 8-K Entry into a Material Def..
05/31 CYTORI THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8-K..
05/31 Cytori and BARDA Execute $13.4 Million Contract Option for Burn Clinical Tria..
05/24 CYTORI THERAPEUTICS : Logs Final 48 Week Patient Follow Up Visit in Scleroderma ..
05/23 Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
05/23DJFirms Persuade SEC on Profit Metric -- WSJ
05/22DJCompanies Are Winning the Battle Over Adjusted Earnings
05/16 Earnings drag on European shares, though Vodafone lifts telcos
05/09 French outbound M&A driven to decade high by big deals
05/06DJProfits Jump, Spending Lags -- WSJ
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
2016 Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q1 2016 Results - Earnings Ca..
2016 Cytori Therapeutics EPS in-line, beats on revenue
2016 Cytori Cell Therapy an Orphan Drug in Europe for scleroderma-related hand dys..
2016 Notable earnings after Tuesday?s close
2016 Cytori's late-stage study of ECCS-50 in scleroderma 50% enrolled; study to co..
Advertisement
Chart CYTORI THERAPEUTICS INC
Duration : Period :
Cytori Therapeutics Inc Technical Analysis Chart | CYTX | US23283K1051 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 5,10 $
Spread / Average Target 405%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Marc H. Hedrick President, Chief Executive Officer & Director
David M. Rickey Chairman
Tiago Girão CFO, Vice President & Head-Investor Relations
John K. Fraser Chief Scientist
Mark T. Marino Chief Medical Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYTORI THERAPEUTICS IN..-4.14%33
MEDTRONIC PLC24.65%121 584
BAXTER INTERNATIONAL36.85%32 555
ZIMMER BIOMET HOLDINGS..25.38%25 653
C R BARD INC40.65%22 853
HOYA CORPORATION14.51%19 886
More Results